{"title":"类风湿因子升高的纤维肌痛与治疗反应不佳有关，但与类风湿关节炎的进展无关。前瞻性队列研究。","authors":"Freddy Liñán Ponce, Juan Leiva Goicochea, David Sevilla Rodríguez, Elmer Hidalgo Bravo, Ginna Obregón Atanacio, Inés Loyola Macalapú, Paola Jáuregui Rojas, Jackeline Yampufe Canani","doi":"10.1016/j.reumae.2024.10.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Objetive</h3><div>Evaluate response to treatment and progression to rheumatoid arthritis (RA) in patients with fibromyalgia (FM) associated with elevated rheumatoid factor (RF).</div></div><div><h3>Material and methods</h3><div>Prospective cohort study. The sample consisted of 124 patients with FM: 62 with high RF (>20 U/mL) and 62 with negative RF (0−20 U/mL). All patients were evaluated using FM treatment improvement score (FIQR) and progression to RA according to EULAR/ACR 2010 criteria at 6 and 12 months. Pearson's χ<sup>2</sup> test for homogeneity was used to relate variables of improvement to FM treatment and progression to RA.</div></div><div><h3>Results</h3><div>The response to treatment was lower in the high RF group (24 and 20 patients improved at 6 and 12 months, respectively, compared to 45 and 38 patients in the negative RF group), with a significant difference. Progression to rheumatoid arthritis was similar in both groups (5 in the high RF group and 4 in the negative RF group), with a non-significant relationship.</div></div><div><h3>Conclusions</h3><div>FM with elevated RF is associated with a poor therapeutic response but not with progression to RA.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 9","pages":"Pages 459-462"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Fibromyalgia with elevated rheumatoid factor is associated with poor therapeutic response but not with progression to rheumatoid arthritis. Prospective cohort study\",\"authors\":\"Freddy Liñán Ponce, Juan Leiva Goicochea, David Sevilla Rodríguez, Elmer Hidalgo Bravo, Ginna Obregón Atanacio, Inés Loyola Macalapú, Paola Jáuregui Rojas, Jackeline Yampufe Canani\",\"doi\":\"10.1016/j.reumae.2024.10.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objetive</h3><div>Evaluate response to treatment and progression to rheumatoid arthritis (RA) in patients with fibromyalgia (FM) associated with elevated rheumatoid factor (RF).</div></div><div><h3>Material and methods</h3><div>Prospective cohort study. The sample consisted of 124 patients with FM: 62 with high RF (>20 U/mL) and 62 with negative RF (0−20 U/mL). All patients were evaluated using FM treatment improvement score (FIQR) and progression to RA according to EULAR/ACR 2010 criteria at 6 and 12 months. Pearson's χ<sup>2</sup> test for homogeneity was used to relate variables of improvement to FM treatment and progression to RA.</div></div><div><h3>Results</h3><div>The response to treatment was lower in the high RF group (24 and 20 patients improved at 6 and 12 months, respectively, compared to 45 and 38 patients in the negative RF group), with a significant difference. Progression to rheumatoid arthritis was similar in both groups (5 in the high RF group and 4 in the negative RF group), with a non-significant relationship.</div></div><div><h3>Conclusions</h3><div>FM with elevated RF is associated with a poor therapeutic response but not with progression to RA.</div></div>\",\"PeriodicalId\":94193,\"journal\":{\"name\":\"Reumatologia clinica\",\"volume\":\"20 9\",\"pages\":\"Pages 459-462\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reumatologia clinica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2173574324001266\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reumatologia clinica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173574324001266","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Fibromyalgia with elevated rheumatoid factor is associated with poor therapeutic response but not with progression to rheumatoid arthritis. Prospective cohort study
Objetive
Evaluate response to treatment and progression to rheumatoid arthritis (RA) in patients with fibromyalgia (FM) associated with elevated rheumatoid factor (RF).
Material and methods
Prospective cohort study. The sample consisted of 124 patients with FM: 62 with high RF (>20 U/mL) and 62 with negative RF (0−20 U/mL). All patients were evaluated using FM treatment improvement score (FIQR) and progression to RA according to EULAR/ACR 2010 criteria at 6 and 12 months. Pearson's χ2 test for homogeneity was used to relate variables of improvement to FM treatment and progression to RA.
Results
The response to treatment was lower in the high RF group (24 and 20 patients improved at 6 and 12 months, respectively, compared to 45 and 38 patients in the negative RF group), with a significant difference. Progression to rheumatoid arthritis was similar in both groups (5 in the high RF group and 4 in the negative RF group), with a non-significant relationship.
Conclusions
FM with elevated RF is associated with a poor therapeutic response but not with progression to RA.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
